Overview

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Status:
COMPLETED
Trial end date:
2025-06-13
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Midazolam